MedTrace Logo

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

NCT00920218 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2017-12-12

Study results available
· View outcomes & findings →

Summary

The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.

Conditions

  • Herpes Zoster

Interventions

BIOLOGICAL

Herpes Zoster Vaccine 1437173A

Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.

BIOLOGICAL

Placebo vaccine (saline)

1 or 3 doses of Placebo (saline) injected intramuscularly.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-14
Primary Completion
2011-04-26
Completion
2012-03-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00920218 on ClinicalTrials.gov